Informed Consent Form Example for Research

HUMAN RESEARCH PARTICIPANT INFORMED CONSENT & AUTHORIZATION AGREEMENT

DOCUMENT CONTROL & META-DATA

• Effective Date: [Effective Date, e.g., October 24, 2023]
• Document Version: [Version Number, e.g., 3.2]
• Protocol ID / IRB Reference: [Institutional Review Board Protocol Number]
• Jurisdiction / Scope: [Applicable State/Country, e.g., State of Delaware, United States]
• Principal Investigator: [Principal Investigator Full Name, Title, and Affiliation]

---

1. OFFICIAL NOTICE & LEGAL DISCLAIMER

LEGAL NOTICE: This document is a template legal instrument drafted for clinical, academic, and corporate research operations. It is designed to secure legally effective informed consent under applicable human subject regulations (including, where applicable, 45 CFR 46, 21 CFR 50/56, and the General Data Protection Regulation [GDPR]). Execution of this document establishes a binding legal and ethical agreement between the Researcher and the Participant. Modification of this template without prior review by qualified legal counsel or the governing Institutional Review Board (IRB) / Ethics Committee may invalidate compliance protections.

---

2. PARTIES & DEFINITIONS

This Informed Consent and Authorization Agreement ("Agreement") is entered into by and between:

• Research Institution / Sponsor: [Legal Entity Name of Institution/Company], having its principal place of business at [Physical Address] ("Institution"), and
• Participant: [Full Legal Name of Participant], residing at [Participant Physical Address] ("Participant" or "Subject").

For the purposes of this Agreement, the following terms shall have the ascribed meanings:

1. "Study" refers to the research protocol titled [Full Official Title of the Research Study].
2. "PHI" (Protected Health Information) and "PII" (Personally Identifiable Information) refer to any data collected during the Study that identifies or can be reasonably linked to the Participant.
3. "Investigational Product" refers to [Drug, Device, Software, or Intervention being tested].

---

3. OPERATIVE CLAUSES & TERMS

SECTION 1: PURPOSE OF THE RESEARCH STUDY

1.1. Invitation & Objective: The Participant is being invited to take part in the Study. The primary objective of this research is to [State the scientific purpose, hypothesis, or objective of the study in plain language]. 1.2. Voluntary Participation: Participation in this Study is entirely voluntary. The Participant may refuse to participate or discontinue participation at any time without penalty, loss of benefits, or adverse impact on standard medical care or employment status.

SECTION 2: STUDY PROCEDURES & DURATION

2.1. Procedures: If the Participant agrees to take part, they will undergo the following procedures: [List specific procedures, e.g., blood draws, surveys, interviews, dosing schedules, imaging, lasting duration per visit]. 2.2. Time Commitment: The total duration of the Participant's involvement in the Study is estimated to be [Number of days/weeks/months], requiring [Number] visits/sessions, each lasting approximately [Number] minutes/hours. 2.3. Randomization & Blinding: [If applicable, include: "Participants will be assigned by chance (randomized) to one of [Number] study arms. Neither the Participant nor the research team will know which intervention the Participant is receiving."].

SECTION 3: RISKS, DISCOMFORTS, & INCONVENIENCES

3.1. Foreseeable Risks: Participation in this Study may entail certain risks, including but not limited to:

• Physical Risks: [e.g., bruising, localized pain, allergic reactions to investigational product].
• Psychological/Emotional Risks: [e.g., emotional distress from survey questions, anxiety].
• Privacy/Confidentiality Risks: [e.g., potential breach of data security despite administrative safeguards]. 3.2. Unforeseen Risks: The Investigational Product or procedures may involve risks that are currently unforeseeable. The Participant will be notified in a timely manner of any new findings or significant developments that may affect their willingness to continue participation. 3.3. Pregnancy / Embryonic Risk: [If applicable: "The procedures and/or interventions in this Study may involve unforeseeable risks to an embryo or fetus. Pregnant or nursing individuals are excluded from participation."].

SECTION 4: POTENTIAL BENEFITS

4.1. Direct Benefits: The Participant [may / will not] directly benefit from taking part in this Study. Potential direct benefits include [Describe any direct medical or therapeutic benefit, or state: "There is no guarantee of direct medical benefit to the Participant."]. 4.2. General Benefits: Information gathered from this Study may contribute to scientific knowledge, medical advancement, and the development of [Describe broader societal or commercial benefits].

SECTION 5: COMPENSATION & COSTS

5.1. Participant Compensation: The Participant will receive [$Amount] per [visit/completion] for their time, travel, and inconvenience, up to a total maximum of [$Total Amount]. Payment terms and tax reporting requirements are subject to [Institution Name] accounting policies. 5.2. Costs: The Participant, their insurance provider, or health plan will not be billed for the Investigational Product or specialized procedures required solely for research purposes. Standard of care treatments remain the financial responsibility of the Participant or their insurer.

SECTION 6: CONFIDENTIALITY & DATA PROTECTION

6.1. Data Collection & Access: Records identifying the Participant will be kept confidential to the extent permitted by law. Authorized representatives of the Institution, the Sponsor ([Sponsor Name]), the IRB, and regulatory authorities (such as the U.S. Food and Drug Administration [FDA] or data protection authorities under GDPR) may inspect research records. 6.2. HIPAA / Privacy Authorization: By signing this Agreement, the Participant authorizes the collection, use, and disclosure of their PHI/PII for the purposes of the Study. This authorization does not have an expiration date. 6.3. Data De-identification: Research data may be de-identified and used for future research studies or shared with third parties without obtaining additional informed consent from the Participant.

SECTION 7: COMPENSATION FOR INJURY

7.1. Treatment of Injury: In the event of physical injury resulting directly from research procedures, emergency medical treatment will be provided by [Hospital/Facility Name]. 7.2. Financial Coverage: Financial compensation for lost wages, specialized long-term care, or pain and suffering is [state policy, e.g., "not automatically provided by the Institution or Sponsor" or describe specific insurance coverage]. Signing this waiver does not waive legal rights to seek legal recourse where negligence is proven.

SECTION 8: RIGHT TO WITHDRAW OR TERMINATE

8.1. Withdrawal Process: The Participant may withdraw from the Study at any time by notifying the Principal Investigator in writing at [PI Email Address]. 8.2. Investigator Termination: The Principal Investigator, Sponsor, or IRB may terminate the Participant’s participation without consent if the Participant fails to follow study directions, if it is discovered the Participant does not meet eligibility criteria, or if continuation would endanger the Participant's health.

---

4. SIGNATURES & ACKNOWLEDGMENT BLOCK

By signing below, the Participant (or the Participant’s legally authorized representative) acknowledges that:

1. They have read and fully understand this Informed Consent and Authorization Agreement.
2. They have had the opportunity to ask questions, and all questions have been answered to their satisfaction.
3. They voluntarily agree to participate in the Study and authorize the use of their data as described herein.
4. They have received a copy of this signed and executed document for their personal records.

PARTICIPANT / LEGAL REPRESENTATIVE

• Printed Name: [Participant Full Legal Name]
• Signature: ____________________________________________________
• Date: [DD/MM/YYYY]
• Capacity (if signing as a Representative): [e.g., Parent, Legal Guardian, Power of Attorney]

---

PRINCIPAL INVESTIGATOR OR DESIGNATED OBTAINING CONSENT

I certify that I have explained the nature, purpose, potential benefits, and foreseeable risks of this Study to the Participant, and that they have freely consented to participation.

• Printed Name of Person Obtaining Consent: [Investigator/Coordinator Full Name]
• Signature: ____________________________________________________
• Date: [DD/MM/YYYY]

---

5. STEP-BY-STEP EXECUTION GUIDE

1. Pre-Consent Briefing: The Principal Investigator or a formally delegated and trained member of the research team must conduct a verbal review of this document with the Participant, ensuring adequate time for comprehension and question-and-answer interaction.
2. Concurrent Execution: Both the Participant (or authorized representative) and the designated study personnel must physically or via a validated 21 CFR Part 11 / eIDAS-compliant electronic signature platform execute the signature block concurrently.
3. Record Retention & Distribution: Provide an exact, fully executed copy of this Agreement to the Participant immediately upon signing. File the original master executed document securely within the Trial Master File (TMF) or Investigator Site File (ISF) in compliance with institutional retention schedules (minimum 6-10 years post-study closeout).
4. Protocol Compliance Audit: Ensure the executed document date precedes the initiation of any protocol-specific procedures; backdating is strictly prohibited.